Introduction
The design and the synthesis of targeting molecules for 10 diagnostic and therapeutic applications represent a major goal in cancer medicine. To this end, peptide ligands for various targets have been identified using combinatorial libraries 1 or phage display method. 2 To attain improved activity and receptor selectivity, it is often essential to restrict the 15 conformational space of peptides by using them in a cyclic form. 3 In this context, cyclic peptides encompassing RGD (Arg-Gly-Asp) sequence have served as the basis for the development of potent peptide ligands used to selectively target the α V β 3 integrin. 4 The latter represents an attractive 20 target for cancer therapeutic purposes. 5 Furthermore, it is well known that the multivalent display of a ligand enhances the binding strength of the ligand to its receptor and can promote receptor-mediated internalisation of the bound entity. 6 Today, the principle of multivalency has then been recognized as an 25 important strategy for the design of synthetic ligands. 7 The effect of multivalency in ligand binding was particularly demonstrated for glycoconjugates, 8 and for peptide ligands.
9
Enhancements of biological activity were especially obtained from multivalent RGD (Arg-Gly-Asp) peptide ligand used to 30 target cell surface receptors such as α V β 3 integrin. 10 Recently, we have shown that tetrameric RGD-containing scaffolds exhibit desirable biological properties for tumour imaging 11 and for targeted drug delivery. 12 These compounds contain a cluster of four copies of a cyclo [-RGDfK-] 35 monomer grafted onto a cyclic decapeptide scaffold (Fig. 1) . Pioneering work aimed at studying the effect of the multivalency parameter in terms of interaction between the ligand and the target receptor and examining the contribution of each c [-RGDfK-] motif. For this purpose, we designed an 40 array of peptide derivatives containing from one to four copies of the c[-RGDfK-] monomer (Fig. 1) . 13 In order to obtain ligands with similar shape, similar steric hindrance and close molecular weights, which is essential for their comparison in vitro, we opted to substitute c [-RGDfK-] for 45 non sense c [-RβADfK-] motifs in the ligands whose valency was lower than four. We used a combinatory assembling strategy to explore all possible positions of the RGD motifs on the cyclodecapeptide scaffold. Consequently, we were unable to isolate the different isomers that differ in the position of 50 cyclic RGD pentapeptides onto the cyclodecapeptide scaffold. To overcome this problem, we recently reported an orthogonal chemoselective ligation strategy that allow access to well defined biomolecular assemblies by exploiting the Huisgen dipolar cycloaddition and the oxime bond formation. Following this strategy, herein we describe the synthesis of new multivalent RGD compounds such as the fluorescent carbohydrate conjugate 1 (Scheme 1). The incorporation of the carbohydrate moiety may provide an enhanced solubility and clearance. With the molecules in hand, we then 60 concentrated our work on assessing biological activities to determine the potency of the different RGD-containing compounds. 16 To introduce suitable functions within peptide moities, we synthesized building blocks such as compounds 3 and 4 which contain protected serine (masked aldehyde) and alkyne groups, respectively (Scheme 1). The 75 use of building blocks during the solid-phase peptide synthesis (SPPS) reduces the number of steps involved for the construction of such conjugates. chemoselective ligations were prepared following rigorously the standard Fmoc/t-Bu SPPS procedure using PyBOP as coupling reagent. The head-to-tail cyclizations provided the desired cyclodecapeptide scaffolds 5 and 6. Deprotection of serine residue using a concentrated TFA solution followed by 10 a subsequent oxidation with periodate 18 afforded key intermediates 7 and 8, isolated in sufficient purity to carry out subsequent chemoselective assemblies. In parallel, RGDcontaining cyclopentapeptide 9 bearing the prerequisite azide function and aminooxy-carbohydrate 10 were prepared as 15 described.
14,8g Very recently, we have shown that cyclopeptide assemblies are possible by means of orthogonal oxime and copper-mediated click reactions in a stepwise or in a one-pot approach.
14 The latter method is much desired, as it avoids lengthy separation process and purification of intermediates 20 while increasing overall chemical yield. Biomolecular ligations of azidopeptide 9 and aminooxy-carbohydrate 10 were then performed on either molecular scaffold 7 or 8. Peptides 7, 9 (6 equiv.) and carbohydrate 10 (3 equiv.) were applied under mild acidic conditions using a solution 25 containing dilute acetic acid and copper microsize powder. Rapid oxime ligation of 10 was observed ( Figure 2 ). Neutralizing the pH resulted in complete disappearance of the intermediate and the exclusive formation of the expected compound 2. To evaluate the RGD-containing compounds for further in vivo studies, we decided to introduce a fluorescent reporter such as Cyanine 5 (Cy5) because its near-infra red (NIR) band (λ em = 670 nm) can penetrate tissue up to 6 cm allowing non invasive optical imaging in small animals. Furthermore, this 5 NIR band is absent of interfering biofluorescence. For this purpose, the intermediate 11 was synthesized according the procedure described above. Cy5 dye was then introduced at the lysine side-chain of 11 under neutral conditions (pH 8.0) affording the fluorescent conjugate 1 in 72% yield after RP-10 HPLC purification. Compounds 1 and 2 were characterized by ES-MS and the observed molecular weights were found in excellent agreement with the calculated values.
To study the contribution of each c [-RGDfK-] motif, an array of molecules 12-19 was designed and prepared 15 according to the method previously described (Figure 3 ). 12a,14 Briefly, RGD ligands and nonsense RβAD peptides were introduced onto the scaffold by using respectively the Huisgen dipolar cycloaddition and orthogonal oxime bond formation, the latter providing shorter linker.
20

Biological assays
The adhesion potency of the different multivalent RGDcontaining peptides was first determined using a traditional ELISA-type inhibition assay. In this experiment, we measured the efficiency of peptides to compete with vitronectin, the encompassing three RGD units displayed the best IC50 (2.8 µM). We previously showed that compounds including three or four RGD ligands exhibit close IC50. 13 We argue that the shorter oxime linker used to graft non-sense RβAD peptide within molecule 15 generates less steric hindrance than 55 unbinded RGD moieties within molecules 2, 12 or 13 while the RGD-containing compound binds to α V β 3 receptor. We then measured the capacity of the molecules to target 65 tumour in mouse. Figure 4 shows typical FRI images of nude mice bearing an subcutaneous human TS/A-pc tumour at different time points after intravenous (iv) injection of 10 nmol fluorescent molecules (i.e. 1 or 19) (See also the Supplementary Information). Strong signal is observed in the 70 kidneys reflecting the prominent and fast renal excretion of RGD-containing molecules as previously shown.
11 One hour postinjection, fluorescent molecules accumulate in the tumour but the whole body is also fluorescent due to the presence of unbound circulating molecules. The average values for the 75 tumour/skin ratios were found to be similar for mice treated with 1 and for mice treated with 19 (respectively 1.39 ± 0.37 and 1.32 ± 0.15) (See Table S1 in the Supplementary Information). The contrast (tumour/skin ratio) was found to be statistically better with 1 ( Figure 4D (161 mg, 100 µmol) was carried out in a solution containing 10 mL of TFA/H 2 O (95:5) for 2 h at room temperature. The product was isolated after removal of solvents under reduced pressure and precipitation from Et 2 O. A serine oxidation by an aqueous solution containing NaIO 4 (10 equiv.) afforded the 45 peptide 7. The crude product was directly purified by using RP-HPLC affording the compound 7 as a white powder. (72 mg, 48 µmol, 48 % yield 
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